When it comes to cancer research, Dr. Clay Siegall stands out from the crowd. This guy is the real deal when it comes to the fight against cancer, and his biotech company Seattle Genetics, is one of the leading research organizations in the world. Seattle Genetics specializes in antibody-drug conjugates. It’s also focused on the commercialization and developed of these life saving drugs. These powerful medications attack cancerous cells within the body and eradicates them with an injection of cell-killing agents. Unlike cancer treatments of the past that would leave the patient extremely sick, these advanced therapies tend to decrease the ill side effects.
Siegall is always reporting and announcing any new finds or information when it comes to fighting cancer. He blogs on a regular basis, and many of his blogs report on any recent upcoming trials for the medications. He spoke on the pivotal CASCADE trial, and how the medications will drastically improve the overall quality of life for older survivors. He’s also spoken on the innovative breast cancer medication known as SGN-LIV1A. Even his social media accounts are loaded with plenty of breaking news articles or general information of the industry.
When it comes to getting things done, Seattle Genetics is at the apex of the industry. Chief Executive Officer Clay Siegall is also a founding member of the company and he serves as its president. The guy literally has a full schedule. His very own personal desire is to see that cancer is eradicated, which is why he works extremely hard to get results. The guy has helped to generate over $1.2 billion through fundraising. Thanks to the amount of funds being raised, the company can afford to purchase the necessary technology to keep this cancer fighting engine going. This not only keeps Seattle Genetics at the forefront of the industry, it provides reassurance to the patients.
Dr. Siegall is highly educated with numerous degrees. He’s been working in the industry for decades, and he’s built a solid reputation of success. With many new drugs in the pipeline, Seattle Genetics will be stepping its game up even more in the years to come.